This section documents the public biology behind AVX-1: norepinephrine regulation, the α2A-adrenergic autoreceptor and the signalling context relevant to state-dependent positive allosteric modulation.
The reviews trace each program-relevant statement to its evidence class and source. Published findings, Aeviant interpretation, program objectives and limitations are identified separately.
Science content reviewed August 21, 2026.
Norepinephrine signalling is regulated across central and peripheral tissues through synthesis, release, reuptake, metabolism, receptor signalling, and feedback. This review describes the public biology relevant to AVX-1 and the limits of what can be inferred from it.
The α2A-adrenergic autoreceptor participates in inhibitory norepinephrine feedback. Its effects vary by tissue, circuit, activity pattern, and experimental context. This review separates that published biology from Aeviant’s interpretation and the AVX-1 program objective.
Ongoing tonic activity and transient phasic responses vary with vigilance, sensory events, task state, and experimental context. This review describes the observations and the evidence required to evaluate AVX-1 pharmacology.
Public claims organized by evidence type, relevance, limitations, and source, with Aeviant interpretation kept separate from published findings.
Program-specific context is available in the AVX-1 review.